CoChat

Targeting senescence as an anticancer therapy

Open access
Bousset, Laura, Gil, Jesús · 2022 · Molecular Oncology
Cited by 105

The DOI matches its Crossref record; 129 of the 129 references it cites were found in a registry or an index.

Abstract

Cellular senescence is a stress response elicited by different molecular insults. Senescence results in cell cycle exit and is characterised by multiple phenotypic changes such as the production of a bioactive secretome. Senescent cells accumulate during ageing and are present in cancerous and fibrotic lesions. Drugs that selectively kill senescent cells (senolytics) have shown great promise for the treatment of age‐related diseases. Senescence plays paradoxical roles in cancer. Induction of senescence limits cancer progression and contributes to therapy success, but lingering senescent cells fuel progression, recurrence, and metastasis. In this review, we describe the intricate relation between senescence and cancer. Moreover, we enumerate how current anticancer therapies induce senescence in tumour cells and how senolytic agents could be deployed to complement anticancer therapies. “One‐two punch” therapies aim to first induce senescence in the tumour followed by senolytic treatment to target newly exposed vulnerabilities in senescent tumour cells. “One‐two punch” represents an emerging and promising new strategy in cancer treatment. Future challenges of “one‐two punch” approaches include how to best monitor senescence in cancer patients to effectively survey their efficacy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/1878-0261.13312

Cites

129 of 129 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 129 references

Research works printed but not linked: 137

  1. 10.1091/mbc.e11-10-0884 · DOI · Paper page
  2. 10.1016/0014-4827(61)90192-6 · DOI · Paper page
  3. 10.1038/345458a0 · DOI · Paper page
  4. 10.1016/j.cell.2008.06.049 · doi:10.1016/j.cell.2008.06.049 · Paper page
  5. 10.1158/0008-5472.CAN-20-0506 · DOI · Paper page
  6. 10.3389/fonc.2017.00278 · DOI · Paper page
  7. 10.1074/jbc.C300023200 · DOI · Paper page
  8. 10.1016/j.molcel.2021.10.017 · DOI · Paper page
  9. 10.1038/s41416-022-01787-6 · DOI
  10. 10.1038/nrc2603 · DOI · Paper page
  11. 10.1158/0008-5472.CAN-08-2970 · DOI · Paper page
  12. 10.1016/j.arr.2016.05.011 · DOI
  13. 10.1016/j.canlet.2020.06.019 · DOI · Paper page
  14. Chang BD, 1999, A senescence‐like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents, Cancer Res, 59, 3761
  15. 10.1038/s41419-018-0303-9 · DOI · Paper page
  16. Wang X, 1998, Evidence of cisplatin‐induced senescent‐like growth arrest in nasopharyngeal carcinoma Cells1, Cancer Res, 58, 5019
  17. 10.1038/sj.bjc.6600711 · DOI · Paper page
  18. 10.1158/0008-5472.CAN-04-2633 · DOI · Paper page
  19. 10.1158/0008-5472.CAN-18-1733 · DOI · Paper page
  20. 10.1371/journal.pone.0055665 · DOI · Paper page
  21. 10.1038/sj.bjc.6604017 · DOI · Paper page
  22. Poele RH, 2002, DNA damage is able to induce senescence in tumor cells in vitro and in vivo, Cancer Res, 62, 1876
  23. 10.1074/jbc.M205477200 · DOI · Paper page
  24. 10.1074/jbc.M807930200 · DOI
  25. 10.1593/neo.05250 · DOI · Paper page
  26. 10.1042/bj20021950 · DOI · Paper page
  27. 10.1038/srep31758 · DOI · Paper page
  28. 10.1016/j.toxlet.2012.08.004 · DOI
  29. 10.18632/oncotarget.2774 · DOI · Paper page
  30. 10.18632/oncotarget.6126 · DOI · Paper page
  31. 10.1158/1078-0432.CCR-15-1421 · DOI · Paper page
  32. 10.3390/cells8121501 · DOI · Paper page
  33. 10.1158/1541-7786.MCR-08-0457 · DOI · Paper page
  34. 10.1016/j.bbrc.2016.06.063 · DOI
  35. 10.1016/j.bcp.2004.06.033 · DOI
  36. 10.18632/aging.102262 · DOI
  37. 10.1080/09553000500168549 · DOI · Paper page
  38. 10.3171/jns.2006.105.1.111 · DOI · Paper page
  39. 10.1038/ncomms15916 · DOI · Paper page
  40. 10.1016/j.yexcr.2017.09.031 · DOI · Paper page
  41. 10.1158/0008-5472.CAN-09-4559 · DOI · Paper page
  42. 10.1158/1541-7786.MCR-20-0915 · DOI
  43. 10.1136/gutjnl-2016-312268 · DOI · Paper page
  44. 10.1038/s41388-018-0332-y · DOI · Paper page
  45. 10.4161/cc.26130 · DOI · Paper page
  46. 10.1016/j.ccell.2017.11.006 · DOI · Paper page
  47. 10.18632/oncotarget.17778 · DOI · Paper page
  48. 10.1158/1078-0432.CCR-18-0372 · DOI
  49. 10.18632/oncotarget.24585 · DOI · Paper page
  50. 10.1158/1535-7163.MCT-13-0137 · DOI · Paper page
  51. 10.1158/0008-5472.CAN-15-1336 · DOI · Paper page
  52. 10.1016/j.neo.2014.05.009 · DOI · Paper page
  53. 10.1016/j.lungcan.2010.10.016 · DOI
  54. 10.1093/gerona/62.3.246 · DOI
  55. 10.4149/neo_2011_01_35 · DOI · Paper page
  56. 10.1158/0008-5472.CAN-04-4608 · DOI · Paper page
  57. 10.1038/onc.2015.435 · DOI
  58. 10.1038/sj.onc.1209049 · DOI · Paper page
  59. 10.1016/j.canlet.2013.02.051 · DOI
  60. 10.1016/j.bbrc.2015.12.070 · DOI
  61. 10.1158/1541-7786.MCR-09-0300 · DOI · Paper page
  62. 10.1158/0008-5472.CAN-14-0386 · DOI
  63. 10.1016/j.pan.2022.03.019 · DOI
  64. 10.1074/jbc.M112.371682 · DOI
  65. 10.1155/2019/9014045 · DOI
  66. 10.1371/journal.pone.0111060 · DOI
  67. 10.18632/oncotarget.2844 · DOI
  68. 10.1002/1878-0261.12477 · DOI
  69. 10.1002/hep.32461 · DOI
  70. 10.1158/1557-3265.OVCA19-A29 · doi:10.1158/1557-3265.ovca19-a29
  71. 10.1002/pros.24342 · DOI
  72. 10.1038/nm.3993 · DOI · Paper page
  73. 10.3802/jgo.2019.30.e26 · DOI
  74. 10.1158/1535-7163.MCT-21-0604 · DOI
  75. Chatterjee P, 2013, PARP inhibition sensitizes to low dose‐rate radiation TMPRSS2‐ERG fusion gene‐expressing and PTEN‐deficient prostate cancer cells. PLOS ONE. Public library of, Science, 8, e60408
  76. 10.1158/0008-5472.CAN-09-4224 · DOI · Paper page
  77. 10.1016/j.lfs.2013.12.009 · DOI
  78. 10.1002/ijc.26239 · DOI
  79. 10.1371/journal.pone.0068003 · DOI
  80. 10.1002/pros.22571 · DOI · Paper page
  81. 10.1016/j.bcp.2021.114765 · DOI
  82. 10.1158/1535-7163.MCT-15-0627 · DOI
  83. 10.18632/oncotarget.25208 · DOI
  84. 10.1002/ijc.26179 · DOI · Paper page
  85. 10.1053/j.gastro.2015.03.016 · DOI
  86. 10.1016/j.radonc.2015.06.026 · DOI
  87. 10.1002/mc.22953 · DOI
  88. 10.1038/jid.2013.6 · DOI
  89. 10.1016/j.phrs.2022.106259 · DOI
  90. 10.1177/1087057109340314 · DOI · Paper page
  91. 10.1038/sj.onc.1203078 · DOI · Paper page
  92. 10.1016/j.canlet.2009.04.015 · DOI
  93. 10.1667/0033-7587(2001)155[0248:RISLGA]2.0.CO;2 · DOI · Paper page
  94. 10.2174/13894501113149990198 · DOI · Paper page
  95. 10.1016/j.trsl.2019.03.006 · DOI · Paper page
  96. 10.1093/jnci/djt212 · DOI · Paper page
  97. 10.1038/s41419-021-03811-8 · DOI · Paper page
  98. 10.1158/1078-0432.CCR-19-1440 · DOI · Paper page
  99. 10.1200/jco.2014.32.15_suppl.2528 · DOI · Paper page
  100. Goel S, 2022, Targeting CDK4 and CDK6 in cancer, Nat Rev Cancer, 1
  101. 10.1016/j.ccell.2020.03.010 · DOI · Paper page
  102. 10.1158/0008-5472.CAN-15-0728 · DOI · Paper page
  103. 10.18632/oncotarget.2673 · DOI
  104. 10.1200/JCO.18.00925 · DOI · Paper page
  105. 10.3390/cancers12123566 · DOI · Paper page
  106. 10.1016/j.bbcan.2008.07.003 · DOI · Paper page
  107. 10.18632/oncotarget.14893 · DOI · Paper page
  108. 10.1158/1078-0432.CCR-06-1405 · DOI · Paper page
  109. 10.3389/fonc.2015.00278 · DOI · Paper page
  110. 10.4161/cc.10.14.16494 · DOI · Paper page
  111. 10.1158/1535-7163.MCT-13-0012 · DOI
  112. 10.1016/j.biopha.2015.07.005 · DOI
  113. 10.1002/ijc.23607 · DOI · Paper page
  114. 10.1038/s41586-018-0387-5 · DOI · Paper page
  115. 10.1126/science.aam7344 · DOI · Paper page
  116. 10.1158/2159-8290.CD-13-0230 · DOI · Paper page
  117. 10.1038/ng.1026 · DOI · Paper page
  118. 10.1038/s41418-020-0564-6 · DOI
  119. 10.1158/1541-7786.MCR-21-0029 · DOI
  120. 10.3390/cancers13143585 · DOI
  121. 10.3390/cancers13030386 · DOI · Paper page
  122. 10.1038/s41467-022-29824-1 · DOI · Paper page
  123. 10.1007/s00018-021-03980-x · DOI
  124. 10.1016/j.jconrel.2020.04.045 · DOI · Paper page
  125. 10.1016/j.ebiom.2021.103646 · DOI · Paper page
  126. 10.1038/nature03579 · DOI · Paper page
  127. 10.3390/cells9071593 · DOI · Paper page
  128. 10.1002/anie.201204663 · DOI · Paper page
  129. 10.3390/jcm8040433 · DOI · Paper page
  130. 10.1056/NEJMoa1009290 · DOI · Paper page
  131. 10.1200/JCO.2012.48.3552 · DOI · Paper page
  132. 10.1158/1078-0432.CCR-10-0802 · DOI
  133. 10.1056/NEJMoa1510016 · DOI · Paper page
  134. 10.1056/NEJMoa1001671 · DOI · Paper page
  135. 10.1002/1878-0261.12807 · DOI · Paper page
  136. 10.1158/1538-7445.AM2018-LB-369 · DOI
  137. 10.1158/1538-7445.AM2019-1146 · DOI · Paper page

Cited by

Metadata

Authors
Bousset, L., & Gil, J.
Venue
Molecular Oncology
Publisher
Wiley
Published
2022-09-23
Volume
16
Issue
21
Pages
3855-3880
ISSN
  • 1574-7891 (ISSN-L)
  • 1878-0261
OpenAlex
W4294794606
Cited by
105
References
129
FWCI
10.14
Type
journal article
Language
en
Open access
gold
Funders
  • Cancer Research UK (C15075/A28647)
  • Medical Research Council Canada (MC_U120085810)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.